Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,676.50
  • Today's Change-13.50 / -0.80%
  • Shares traded2.25m
  • 1 Year change-32.83%
  • Beta0.2097
Data delayed at least 20 minutes, as of May 25 2022 10:20 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals. The Generics business develops and manufactures oral and other non-injectable generic products. The Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in Middle East/North Africa (MENA). The Company’s products are sold in the retail and hospital markets. It also markets its products in Canada, which includes approximately 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products.

  • Revenue in GBP (TTM)2.04bn
  • Net income in GBP336.02m
  • Incorporated2005
  • Employees8.70k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 207 399 2760
  • Fax+44 207 399 2761
  • Websitehttps://www.hikma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HIK:LSE since
Teligent Inc-Sterile Injectable AssetsDeal completed17 Jan 202217 Jan 2022Deal completed-18.46%36.45m
CUSTOpharm IncDeal completed27 Sep 202127 Sep 2021Deal completed-29.74%425.00m
Data delayed at least 20 minutes, as of May 25 2022 10:20 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Genus plc569.80m35.70m1.76bn3.10k49.233.4524.933.080.54280.54288.667.740.6557--5.19184,043.904.073.304.793.85----
Indivior PLC652.89m132.49m2.21bn802.0018.1311.9814.723.380.17320.17320.85470.26230.49061.454.54814,073.209.966.9817.0214.2683.8686.3220.2912.431.618.170.54860.0022.26-5.65238.5142.41-0.5781--
Abcam Plc315.40m3.90m2.55bn1.75k654.933.8955.798.100.0170.0171.382.870.34871.796.68180,228.600.4312--0.4979--71.21--1.24--0.818956.200.2593--------------
Dechra Pharmaceuticals plc640.60m72.90m3.77bn1.95k51.875.8923.165.880.66970.66975.895.900.53751.907.42329,357.306.123.376.873.7956.8856.4711.386.851.7513.570.331497.7818.0419.6963.7234.3778.1817.02
Hikma Pharmaceuticals Plc2.04bn336.02m3.78bn8.70k11.762.018.061.851.441.448.758.460.60021.723.70234,135.009.873.8013.055.2150.9650.9016.456.611.3810.350.255471.439.065.54-2.3222.123.8011.07
Croda International Plc1.89bn320.80m9.42bn6.14k29.435.3821.604.992.292.2913.5212.570.59782.556.02308,003.3010.2111.1711.7513.1649.6943.7117.0816.390.9823.600.346461.7835.918.7359.1310.288.535.70
Data as of May 25 2022. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

26.03%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 23 Feb 202211.20m4.95%
JPMorgan International Bank Ltd.as of 02 Apr 202210.75m4.75%
BlackRock Advisors (UK) Ltd.as of 04 Mar 202210.13m4.48%
Capital Research & Management Co. (World Investors)as of 23 Feb 20227.64m3.38%
Norges Bank Investment Managementas of 02 Apr 20224.24m1.87%
The Vanguard Group, Inc.as of 02 Apr 20223.60m1.59%
Northern Trust Global Investments Ltd. (Securities Lending)as of 02 Apr 20223.33m1.47%
Franklin Templeton Institutional LLCas of 31 Mar 20223.13m1.38%
Capital Research & Management Co. (Global Investors)as of 02 Apr 20222.95m1.31%
Templeton Investment Counsel LLCas of 02 Apr 20221.92m0.85%
More ▼
Data from 31 Dec 2021 - 02 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.